Vivek Ramaswamy (Jeff Rumans/JPM 2020)
November 10, 2020 08:44 AM ESTUpdated 03:40 PM
People
Deals

Vivek Ra­maswamy eyes an I/O vant with up to $2B li­cens­ing deal

Jason Mast

Editor

Has Vivek Ra­maswamy found the seed of his next vant?

On Mon­day, Roivant an­nounced a rare part­ner­ship deal, sign­ing an agree­ment with the Ger­man im­muno …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Se­nior As­traZeneca ex­ec de­tained in Chi­na amid wider in­ves­ti­ga­tion

Pfiz­er to in­vest $1B in Chi­na over next five years — re­ports

Soft RSV sales re­veal a vac­cine mar­ket fail­ing to catch post-Covid mo­men­tum

Stephen Squin­to's JPM life sci­ences team is rais­ing a new fund for lat­er-stage com­pa­nies

Avid Bioser­vices to be sold to pri­vate eq­ui­ty firms for $1.1B

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times